Business Wire

Toshiba's e-STUDIO5005AC Earns Buyers Laboratory's "Highly Recommended" and "Highly Reliable"

26.12.2016 06:00 | Business Wire

Del

Toshiba Tec Corporation (TOKYO:6588) today announced that its latest colour Multi-function peripherals (MFP), the e-STUDIO5005AC received the Buyers Laboratory LLC’s (BLI) “Highly Recommended” and “Highly Reliable” rating. BLI is the leading independent analytical information provider, and from its two-month, 210,000 impression durability test, the company's award-winning MFP performed extremely well in reliability, ease of use and security features.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161225005001/en/

Toshiba Tec Corporation announced that its latest colour Multi-function peripherals (MFP), the e-STU ...

Toshiba Tec Corporation announced that its latest colour Multi-function peripherals (MFP), the e-STUDIO5005AC received the Buyers Laboratory LLC's (BLI) "Highly Recommended" and "Highly Reliable" rating. (Graphic: Business Wire)

The leading independent analytics provider noted the e-STUDIO5005AC’s ideal fit for medium- to large-size workgroups. The recent addition to Toshiba’s award-winning e-STUDIO line also scored high within nine other BLI testing categories including user maintenance, productivity and image quality.

“The Toshiba e-STUDIO5005AC promises to deliver maximum uptime for mid-size to large workgroups, thanks to outstanding reliability and simple procedures for replacing toner, drums and the waste toner container,” said BLI Senior Editor George Mikolay. “In addition, the device’s fast job stream speeds mean it will have no problem remaining productive in environments in which multiple users send multiple types of jobs over the course of the day. And those long-run jobs will not be at the expense of image quality, which proved to be consistent throughout testing and will meet the needs of most business environments.”

They were further impressed by e-STUDIO5005AC’s features of productivity and ease of use: boost scan productivity with fast scan speeds and 300-sheet duplex single-pass feeder, increase office efficiency with Simple Scan and Simple Copy menus by its new user interface, and take advantage of allowing applications to be embedded on to the MFP by the newly introduced e-BRIDGE Next controller.

Moreover, BLI noted that Toshiba’s self-encrypting hard drive with automatic drive invalidation and data overwrite up to 15 times*, and passing the strict U.S. Federal Information processing Standard 140-2, making the MFP ideal for any organization seeking to bolster its data security.

“It is a great honour for us to receive such an evaluation from the most reliable organization,” said Isao Sugehara, Chief Marketing Executive of Toshiba Tec Printing Solutions Business Group. “We believe this is the result that e-STUDIO5005AC has fulfilled all of the necessary needs and offers value for customers. This was achieved by everyone who dedicated to introduce this product”.

* The availability vary from country to country

About Buyers Laboratory LLC

Buyers Laboratory LLC (BLI) is the world's leading independent provider of analytical information and testing services to the document management industry. For over 50 years, buyers have relied on BLI to help them differentiate products' strengths and weaknesses and make the best purchasing decisions, while industry sales, marketing and product professionals have turned to BLI for insightful competitive intelligence and valued guidance on product development, competitive positioning and sales channel and marketing support. BLI also offers private, for-hire testing services that help manufacturers develop and market better products and consumables.

About Toshiba Tec

Toshiba Tec Corporation is a Toshiba’s group company, a leading provider of technology solutions, operating across multiple industries – ranging from retail, education and business services to hospitality and manufacturing. With headquarters in Japan and over 80 subsidiaries worldwide, Toshiba Tec Corporation helps organizations transform the way they create, record, share, manage and display information.

Please visit http://www.toshibatec.co.jp/en/
For Global site please visit http://www.toshibatec.com/global/

Unless otherwise specified and/or credited all images, artwork, text and graphics, logos and logotypes are the copyright and/or trademark of the respective owners. All rights reserved.

Contact information

Media Contact
Toshiba Tec Corporation
Toshihiko “Tommy” Minato, +81-(0)50-3681-5528
Marketing Department
Products, Marketing & Service Division
Printing Solutions Business Group
Toshihiko_Minato@toshibatec.co.jp

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25Pressemelding

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00Pressemelding

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03Pressemelding

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 08:00Pressemelding

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 07:08Pressemelding

Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven

Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 06:00Pressemelding

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom